![]() |
ATEA Pharmaceuticals, Inc. (AVIR) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Atea Pharmaceuticals, Inc. (AVIR) Bundle
Entdecken Sie ATEA Pharmaceuticals, Inc. (AVIR) Finanzielle Aussichten mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Annahmen für Wachstum, Margen und Kosten ein, um den inneren Wert von ATEA Pharmaceuticals, Inc. (AVIR) zu berechnen und Ihren Investitionsansatz zu verfeinern.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | 48.6 | 351.4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 622.49 | -100 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -14.6 | -11.0 | 138.4 | -110.8 | -119.6 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | -22.64 | 39.39 | 100 | 100 | 63.35 | 63.35 | 63.35 | 63.35 | 63.35 |
Depreciation | .0 | .0 | .0 | .3 | .4 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 0.03906812 | 0.00825348 | 100 | 100 | 60.01 | 60.01 | 60.01 | 60.01 | 60.01 |
EBIT | -14.6 | -11.0 | 138.4 | -111.1 | -120.0 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | -22.68 | 39.38 | 100 | 100 | 63.34 | 63.34 | 63.34 | 63.34 | 63.34 |
Total Cash | 21.7 | 850.1 | 764.4 | 646.7 | 578.1 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | 5.8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 11.96 | 0 | 100 | 100 | 62.39 | 62.39 | 62.39 | 62.39 | 62.39 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 0 | 0 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Accounts Payable | .5 | .1 | 4.5 | 2.6 | 4.3 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 0.12337 | 1.29 | 100 | 100 | 60.28 | 60.28 | 60.28 | 60.28 | 60.28 |
Capital Expenditure | .0 | .0 | .0 | -1.9 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | -0.05346164 | -0.00113841 | 100 | 100 | -0.01092001 | -0.01092001 | -0.01092001 | -0.01092001 | -0.01092001 |
Tax Rate, % | -0.75442 | -0.75442 | -0.75442 | -0.75442 | -0.75442 | -0.75442 | -0.75442 | -0.75442 | -0.75442 | -0.75442 |
EBITAT | -14.0 | -10.9 | 121.0 | -107.8 | -120.9 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -13.4 | -17.3 | 131.3 | -111.4 | -118.8 | -4.3 | .0 | .0 | .0 | .0 |
WACC, % | 4.96 | 4.96 | 4.96 | 4.96 | 4.97 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 |
PV UFCF | ||||||||||
SUM PV UFCF | -4.1 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -4 | |||||||||
Net Debt | -141 | |||||||||
Equity Value | 137 | |||||||||
Diluted Shares Outstanding, MM | 83 | |||||||||
Equity Value Per Share | 1.65 |
What You Will Get
- Real Atea Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Atea Pharmaceuticals, Inc. (AVIR).
- Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit Atea's specific needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on Atea's fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections tailored for Atea Pharmaceuticals, Inc. (AVIR).
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility for Atea's financial analysis.
Key Features
- Pre-Loaded Data: Atea Pharmaceuticals' historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: View Atea Pharmaceuticals' intrinsic value recalculated in real time.
- Clear Visual Outputs: Dashboard charts present valuation results and key metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.
How It Works
- 1. Download the Model: Obtain and open the Excel file containing Atea Pharmaceuticals, Inc.'s (AVIR) financial data.
- 2. Adjust Key Variables: Modify essential inputs such as revenue growth rates, discount rates, and research expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Evaluate various projections to assess a range of valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation analysis to bolster your strategic decisions.
Why Choose This Calculator for Atea Pharmaceuticals, Inc. (AVIR)?
- Accuracy: Leverages real Atea financial data to ensure precise calculations.
- Flexibility: Users can easily adjust and test various inputs to suit their needs.
- Time-Saving: Avoid the complexities of creating a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Accurately assess Atea Pharmaceuticals’ fair value before making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
- Consultants: Easily modify the template for client valuation reports.
- Entrepreneurs: Acquire knowledge of financial modeling practices employed by leading pharmaceutical companies.
- Educators: Employ it as a resource to illustrate valuation techniques in the classroom.
What the Template Contains
- Preloaded AVIR Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.